Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Study participants are selected by body-mass criteria, medical history, medication use, and other factors
Last reviewed: April 21, 2026 Updated with Phase 3 TRIUMPH-4 data Primary sources: NEJM, Eli Lilly, ClinicalTrials.gov Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) currently in Phase 3 trials, showing stronger early weight loss data
You assume responsibility for legal compliance, proper handling, storage, and disposal
Reference Gao W, Liu L, Huh E, Gbahou F, Cecon E, Oshima M, Houz L, Katsonis P, Hegron A, Fan Z, Hou G, Charpentier G, Boissel M, Derhourhi M, Marre M, Balkau B, Froguel P, Scharfmann R, Lichtarge O, Dam J, Bonnefond A, Liu J, Jockers R
Take It With You : Dont leave medication in the car during stops
Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist not yet approved by the MHRA or EMA as of 2024
US$ 25.20
US$ 25.52
US$ 24.46
